DRKS00007559进行中（未招募）未知
Pilot Trial on the Combined Therapy of Cytokine Filtration and Granulocyte/Monocyte Adsorption in Sepsis
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 90 Years（—）
- 性别
- All
入选标准
- •Severe sepsis or septic shock,
- •- Acute, septic renal failure and indication for renal replacement therapy,
- •- Age =18 years,
- •- Written informed consent of the patient or next of kin or legally authorized person
排除标准
- •- Pregnant or breast-feeding women,
- •- Age > 90 years,
- •- bleeding risk due to underlying disease or recently performed surgery,
- •- known allergies to components of the extracorporeal therapy,
- •- Contraindications to heparin for anticoagulation including heparin induced thrombocytopenia Type II
- •- previous severe sepsis during the hospital stay (re-Sepsis”),
- •- very poor prognosis (life expectancy < 6 months) due to concomitant disease (except severe sepsis or septic shock),
- •- Aplasia,
- •- currently on chemotherapy.
研究者
相似试验
招募中
3 期
Trial of novel combined therapy between interferon and hyperlipidemia for chronic hepatitis C patientschronic hepatitis type CJPRN-UMIN000005598Kyoto University Graduate School of Medicine Center for Genomic Medicine100
招募中
1 期
Phase 1/2 clinical trial of immunotherapy with fusions of tumor cells and dendritic cells for pediatric refractory brain tumorPediatric refractory brain tumorJPRN-UMIN000031312Jikei University School of Medicine20
招募中
2 期
Combined sublingual immunotherapy VALERGEN-DP and VALERGEN-BT-Asthma-Adults-Phase IIAsthmaBronchial DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System DiseasesEnvironmental IllnessRPCEC00000240ational Center of Bioproducts (BIOCEN)120
进行中（未招募）
不适用
Pilot phase II study of a combined immunotherapy protocol based on oral vaccination and direct intratumoral injection of Salmonella Typhi Ty21a Vivotif in metastatic cutaneous melanoma patients. - NDMetastatic stage III e IV M1a melanomaMedDRA version: 6.1Level: PTClassification code 10042551EUCTR2005-005775-15-ITISTITUTO EUROPEO DI ONCOLOGIA43
进行中（未招募）
不适用
Patients who suffer from T-Prolymphocytic leukemia and have received none or one chemotherapy so far will be treated with Fludarabine, Cyclophosphamide, Mitoxantrone and Alemtuzumab.ntreated patients with T-prolymphocytic leukemia (T-PLL) according to WHO criteria or pretreated patients (max. one previous treatment) with T-PLL .EUCTR2008-001421-34-DEniversity of Cologne, Sponsor-Quality Management16